Background: In patients with venous thromboembolism (VTE), warfarin had been considered
standard of care until the new direct oral anticoagulants (DOACs) were developed. Studies …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

The article focuses on the prescribing considerations of direct oral anticoagulants (DOACs)
for specific patient populations, including those with obesity, renal disease, cancer, and …

Background Due to a paucity of data on the efficacy and safety of direct oral anticoagulants
(DOACs) in patients with a body mass index> 40 kg/m 2 or a weight> 120 kg, the use of …

Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …

Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …

This study integrated 5 United States healthcare claims databases to evaluate the risk of
recurrent venous thromboembolism (VTE) and major bleeding (MB) among VTE patients …

Introduction Guidelines have endorsed non-vitamin K antagonist oral anticoagulants
(NOACs), consisting of factor Xa inhibitors (xabans) and direct thrombin inhibitors, as the first …

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and
venous thromboembolism (VTE) and both occur more frequently in obese patients …

Obesity is a known risk factor for venous thromboembolism (VTE) and poses a unique set of
challenges in anticoagulation management. We report a 10-year experience of VTE …